Hyperion Therapeutics receives orphan drug exclusivity from FDA

theflyonthewall.com

Hyperion Therapeutics announced that the FDA yesterday notified the company that Ravicti Liquid has qualified for orphan drug exclusivity. The orphan exclusivity is for seven years from the date of the approval on February 1.

View Comments (0)